Merz Therapeutics Closes $185M Asset Purchase Agreement with Acorda Therapeutics

Contributed by: Business Wire

Logo

Images

Business Wire associated0

Business Wire associated1

Business Wire embedded0

Tags

Pharmaceutical

Health

Neurology

Clinical Trials

Merz Therapeutics

More Like This

Merz Enters Asset Purchase Agreement With a US-Based Biotech Company

Mundipharma acquires all assets and rights related to REZZAYO® (rezafungin), reinforcing continued commitment to management of infectious diseases and specialty care therapeutic area

Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine

Ferrer Obtains the Distribution Rights for Treprostinil Inhalation Solution Including the Potential Indications for Idiopathic Pulmonary Fibrosis (IPF) and Progressive Pulmonary Fibrosis (PPF)

Ferring Pharmaceuticals bolsters global gene therapy supply chain with European manufacturing facility

Incyte Gains Exclusive Global Development and Commercialization Rights to Tafasitamab (Monjuvi®)

Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets

PR Newswire associated0

Alkermes Highlights Data Presentations Related to its Psychiatry Franchise at Spring 2024 Scientific Conferences